About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1/2NCT00117143

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune throm...

Lead sponsor: Amgen•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Amgen

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Greater than or equal to 3 months history of ITP, regardless of splenectomy status, and completion of at least 1 prior treatment for ITP
•2 of 3 pretreatment platelet counts that were less than 30 x 10\^9/L (if not currently on ITP therapy) or less than 50 x 10\^9/L (if currently receiving corticosteroids for ITP therapy)
•Ability to give informed consent

Exclusion Criteria

•Known history of arterial thrombosis, active malignancy, or bone marrow stem cell disorder

Related studies

Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT07513948 · Thrombotic Thrombocytopenic Purpura, Acquired

Association of TNFAIP3 With Immune-mediated TTP

NCT06928233 · Thrombotic Thrombocytopenic Purpura, Acquired

RECRUITINGPhase 3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235 · Immune Thrombocytopenic Purpura (ITP)

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

NCT04890041 · Primary Immune Thrombocytopenic Purpura

Special Drug Use-results Survey for Long-term Use (Fostamatinib)

NCT06757257 · Chronic Idiopathic Thrombocytopenic Purpura

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 26, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment16

Start dateDec 2002

Last updatedJun 26, 2023

Condition

Thrombocytopenic Purpura

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions